Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0086543 (cataract)
 29,165 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Three different components contribute to the modulation transfer function of the visual system: (1) formation of the optical image (refractive media, pupil); (2) scattering of light in the prereceptoral layers of the retina; (3) neuronal processing in the retina und superior visual centers. In the presence of media opacities or non-correctable refractive errors, the clinical question often arises as to which macular function can be expected under the assumption of normal optical image formation (e.g. prior to cataract extraction, corneal transplantation, or vitrectomy). Simple tests such as light projection, color discrimination, and two-point discrimination cannot provide adequate information about macular function. The same holds true for the global luminance ERG. The X-ray phosphene is obsolete. The Maddox rod (with limitations), transilluminated Amsler grid, and various entoptic phenomena (Purkinje vascular phenomenon, foveal chagrin, Haidinger's brushes, blue field phenomenon) are available as qualitative subjective tests. Maxwellian view systems with pinhole aperture (potential acuity meter PAM) and the interferometers (retinometer, visometer, SITE-IRAS interferometer) provide quantitative subjective methods. The flash VECP is primarily a qualitative objective test that allows semiquantitative acuity prediction under special conditions (unilateral opacities). Psychophysical criteria that are less affected by the quality of the retinal image show promising developments in future subjective tests, e.g. optotypes in positive contrast, optotypes or targets superimposed on a background of optical noise, or hyperacuity. Future objective test developments are pattern VECP or even pattern ERG elicited by interferometric stimulation, speckle VECP and focal ERG.
 ...
PMID:[Predicting visual acuity in media opacities and uncorrectable refractive errors. Assessing so-called "retinal visual acuity"]. 208 91

Background/Aims. To report the safety and efficacy of strontium (Sr(90)) beta radiotherapy as adjuvant treatment for conjunctival melanoma. Methods. A retrospective cohort study was undertaken from 1999 to 2007 of all patients who underwent Sr(90) beta radiotherapy for incompletely excised conjunctival melanoma. Failure of treatment was defined as recurrence of a conjunctival melanoma at the same location following beta radiotherapy. Results. Twenty patients underwent Sr(90) beta radiotherapy for incompletely excised conjunctival melanoma. Median follow-up interval was 59 months (8-152). All patients had conjunctival melanoma involving the bulbar conjunctiva. Underlying diagnoses included PAM with atypia in 60% (12 of 20), PAM without atypia in 15% (3 of 20), and de novo conjunctival melanoma in 25% (5 of 20). Following Sr(90) beta radiotherapy, in 90% (18 out of 20) local control was achieved and visual acuity was not affected in any patient. Three patients (15%) had dry eye symptoms, episcleritis, and descemetcoele, respectively. No cataract or secondary glaucoma was reported. Conclusions. Sr(90) treatment is a very effective adjuvant treatment after excisional biopsy and cryotherapy for conjunctival melanoma with a local success rate of 90%. The treatment is not associated with significant side effects and visual acuity is not affected.
 ...
PMID:The use of strontium-90 Beta radiotherapy as adjuvant treatment for conjunctival melanoma. 2343 Dec 99